In summary, our study comprehensively analyses both CRC cell lines and tissue specimens for known and novel putative predictive markers of EGFR-targeted therapy responses and is the first to identify ATM mutations and E-cadherin expression as potential novel supportive predictive markers for EGFR-targeted therapy. The gene discussed is ATM; the disease is colorectal carcinoma.